drugset / Trial / NCT03956134
Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
This study investigated the pharmacokinetics (how a drug is taken up and excreted from the body), safety, and tolerability of 2 new tapentadol (CG5503) tablet formulations compared to a previously characterized tapentadol prolonged-release (PR) tablet formulation.
Timeline
- Start
- 2005-04
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tapentadol | Small molecule | 116 mg | Oral |
Indications
No indication recorded.